Myrtelle

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

No changes recorded yet. Missing observations do not mean the company has not changed.

Companies in the same space

Competitors picked by an AI model from the funded startups with the most similar descriptions, judged on those descriptions only. A reading, not a verified market map.

• Tern Therapeutics terntx.comDirect competitorBoth develop one-time AAV gene therapies for rare pediatric neurodegenerative CNS diseases.
• Voyager Therapeutics voyagertherapeutics.comDirect competitorBoth develop AAV-based gene therapies targeting serious neurological and CNS diseases.
• Rocket Pharmaceuticals rocketpharma.comPartial overlapBoth develop AAV-based gene therapies for rare inherited diseases, including CNS indications.
• AveXis (Avexis) avexis.comPartial overlapBoth develop gene therapies for rare neurological diseases using AAV-based approaches.
• Capsida Biotherapeutics capsida.comPartial overlapBoth focus on targeted AAV gene therapies for neurological diseases, including CNS delivery.
• Latus Biosciences latusbio.comPartial overlapBoth work on AAV-based gene therapy solutions for CNS disorders.